ReValve Solutions

ReValve Solutions is a private cardiovascular medical device company developing transcatheter therapies for structural heart disease, with an initial focus on transcatheter mitral valve replacement. The company is based in Irvine, California and is led by founder and CEO Julie Logan Sands. Its lead product is the Palmetto System, a next-generation transcatheter mitral valve replacement device designed to preserve left ventricular function and reduce left ventricular outflow tract obstruction risk relative to earlier rigid designs. In November 2023, the company announced a successful first-in-human procedure in Panama using the Palmetto System, indicating that the company has entered early clinical development. ReValve positions its products as less invasive solutions intended to support earlier intervention and ongoing treatment options in structural heart care.